Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study

Pembrolizumab monotherapy and pembrolizumab plus platinum-based chemotherapy are the standard of care for first-line treatment of R/M HNSCC. However, there is a growing unmet need for safe and efficacious treatment options for patients with R/M HNSCC whose disease progressed on or after platinum-based chemotherapy and immunotherapy. The randomized, open-label, phase 2 LEAP-009 (NCT04428151) study is being conducted to evaluate the safety and efficacy of lenvatinib plus pembrolizumab or lenvatinib monotherapy versus chemotherapy in patients with R/M HNSCC whose disease progressed after treatment with platinum-based therapy and a PD-1/L1 inhibitor.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K. Harrington, H.R. Kim, S. Salas, M. Oliva, R. Metcalf, M. Bernsdorf, J.W. Kim, E. Cohen, L.L. Siu, D. Rischin, L. Licitra, J. Vermorken, Q.T. Le, M. Tahara, J.P. Machiels, K. O'Hara, K. Pathiraja, B. Gumuscu, B. Bidadi, B. Burtness Tags: 160 Source Type: research